Adam M. Farkas

Adam M. Farkas

Auto-generated profile, based on publicly available information

Adam M. Farkas

Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute New York, New York

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
LWLi Wang
Li Wang
JSJohn P. Sfakianos
John P. Sfakianos
KBKristin G. Beaumont
Kristin G. Beaumont
GAGuray Akturk
Guray Akturk
AHAmir Horowitz
Amir Horowitz
MGMatthew D. Galsky
Matthew D. Galsky
Purpose: To define dominant molecular and cellular features associated with PD-1/PD-L1 blockade resistance in metastatic urothelial cancer. Experimental Design: We pursued an unbiased approach using bulk RNA sequencing data from two clinical trials to discover (IMvigor 210) and validate (CheckMate 275) pretreatment molecular features associated with resistance to PD-1/PD-L1 blockade in metastatic urothelial cancer. We then generated single-cell RNA sequencing (scRNA-seq) data from muscle-invasive bladder cancer specimens to dissect the cellular composition underlying the identified gene signatures. Results: We identified an adaptive immune response gene signature associated with response and a protumorigenic inflammation gene signature associated with resistance to PD-1/PD-L1 blockade. The adaptive immune response:protumorigenic inflammation signature expression ratio, coined the 2IR score, best correlated with clinical outcomes, and was externally validated. Mapping these bulk gene signatures onto scRNA-seq data uncovered their underlying cellular diversity, with prominent expression of the protumorigenic inflammation signature by myeloid phagocytic cells. However, heterogeneity in expression of adaptive immune and protumorigenic inflammation genes was observed among single myeloid phagocytic cells, quantified as the myeloid single cell immune:protumorigenic inflammation ratio (Msc2IR) score. Single myeloid phagocytic cells with low Msc2IR scores demonstrated upregulation of proinflammatory cytokines/chemokines and downregulation of antigen presentation genes, were unrelated to M1 versus M2 polarization, and were enriched in pretreatment blood samples from patients with PD-L1 blockade–resistant metastatic urothelial cancer. Conclusions: The balance of adaptive immunity and protumorigenic inflammation in individual tumor microenvironments is associated with PD-1/PD-L1 resistance in urothelial cancer with the latter linked to a proinflammatory cellular state of myeloid phagocytic cells detectable in tumor and blood. See related commentary by Drake, p. 4139

7 June 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MTMichelle A. Tran
Michelle A. Tran
DYDina Youssef
Dina Youssef
SSSanjana Shroff
Sanjana Shroff
DCDisha Chowhan
Disha Chowhan
KBKristin G Beaumont
Kristin G Beaumont
NBNina Bhardwaj
Nina Bhardwaj
Due to bladder tumors’ contact with urine, urine-derived cells (UDCs) may serve as a surrogate for monitoring the tumor microenvironment (TME) in bladder cancer (BC). However, the composition of UDCs and the extent to which they mirror the tumor remain poorly characterized. We generated the first single-cell RNA-sequencing of BC patient UDCs with matched tumor and peripheral blood mononuclear cells (PBMC). BC urine was more cellular than healthy donor (HD) urine, containing multiple immune populations including myeloid cells, CD4+ and CD8+ T cells, natural killer (NK) cells, B cells, and dendritic cells (DCs) in addition to tumor and stromal cells. Immune UDCs were transcriptionally more similar to tumor than blood. UDCs encompassed cytotoxic and activated CD4+ T cells, exhausted and tissue-resident memory CD8+ T cells, macrophages, germinal-center-like B cells, tissue-resident and adaptive NK cells, and regulatory DCs found in tumor but lacking or absent in blood. Our findings suggest BC UDCs may be surrogates for the TME and serve as therapeutic biomarkers.

21 September 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
HYHaocheng Yu
Haocheng Yu
JSJohn P. Sfakianos
John P. Sfakianos
LWLi Wang
Li Wang
YHYang Hu
Yang Hu
JDJorge Daza
Jorge Daza
David  MulhollandDavid Mulholland
David Mulholland
Most bladder cancers are poorly responsive to immune checkpoint blockade (ICB). With the need to define mechanisms of de novo resistance, including contributions from the tumor microenvironment (TME), we used single-cell transcriptional profiling to map tumor-infiltrating lymphocytic and myeloid cells in 10 human bladder tumors obtained from patients with a history of smoking either with or without previous ICB. Human datasets were qualitatively compared with single cell datasets from the BBN carcinogen-induced mouse model of bladder cancer, which was poorly responsive to PD-L1 blockade. We applied an established signature of acquired ICB resistance to these human and murine datasets to reveal conservation in EMT and TGFβ ICB resistance signatures between human–mouse stromal and myeloid cells. Using TCGA transcriptional datasets and deconvolution analysis, we showed that patients with a history of smoking and bladder tumors high in M2 macrophage tumor content had a significantly worse survival outcome compared with nonsmokers who were M2 high. Similarly, BBN-induced tumors were high in M2 macrophage content and contained exhausted T–NK cells, thereby modeling the identified TCGA patient subpopulation. The combined targeting of TGFβ + PD-L1 reverted immune cell exclusion and resulted in increased survival and delayed BBN-induced tumor progression. Together, these data support a coordinated role for stromal and myeloid cell populations in promoting de novo resistance to PD-L1 blockade, particularly in patients with a history of smoking. Significance: Most patients with bladder cancer do not respond to ICB targeting of the PD-L1 signaling axis. Our modeling applied a de novo resistance signature to show that tumor-infiltrating myeloid cells promote poor treatment response in a TGFβ-dependent mechanism.

27 February 2026 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MTMichelle A. Tran
Michelle A. Tran
BCByuri Angela Cho
Byuri Angela Cho
SISudeh Izadmehr
Sudeh Izadmehr
SYSeong-Keun Yoo
Seong-Keun Yoo
DYDina Youssef
Dina Youssef
NBNina Bhardwaj
Nina Bhardwaj
Immune checkpoint blockade (ICB) has revolutionized treatment for urothelial bladder cancer, yet response rates remain limited. Inflammation promotes disease progression and treatment resistance, with macrophages shaping the tumor microenvironment (TME). Although elevated blood C-reactive protein (CRP) is associated with poor clinical outcomes in urothelial bladder cancer, its relationship to the TME remains unclear. In this study, we show that elevated plasma IL6 and CRP associate with increased tumor macrophage infiltration across multiple ICB-treated cohorts. Single-cell RNA sequencing (RNA-seq) of the largest urothelial bladder cancer atlas to date, integrated with bulk RNA-seq, identifies enrichment of immunosuppressive SPP1+ macrophages in TMEs from patients with high plasma IL6. Spatial and functional analyses demonstrate that SPP1+ macrophages suppress T-cell activity partly via IL6 signaling, whereas CXCL9+ macrophages promote T-cell activation. These findings link systemic inflammation to local immune dysfunction and define a macrophage-driven axis associated with ICB resistance and therapeutic targets to improve immunotherapy outcomes in urothelial bladder cancer. Significance: Single-cell and bulk RNA-seq, spatial analyses, and functional experiments identify opposing SPP1+ and CXCL9+ macrophage programs that regulate T-cell function and ICB therapy response in bladder cancer. Elevated plasma CRP and IL6 mark SPP1+ macrophage–driven immune suppression, defining a targetable IL1β/IL6 axis that contributes to immunotherapy resistance.

3 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
AFAdam M. Farkas
Adam M. Farkas
MTMichelle A. Tran
Michelle A. Tran
DYDina Youssef
Dina Youssef
SBSreekumar Balan
Sreekumar Balan
JNJenna H. Newman
Jenna H. Newman
NBNina Bhardwaj
Nina Bhardwaj
Summary: NK cells are innate lymphocytes critical for surveillance of viruses and tumors, however the mechanisms underlying NK cell dysfunction in cancer are incompletely understood. We assessed the effector function of NK cells from bladder cancer patients and found severe dysfunction in NK cells derived from tumors versus peripheral blood. While both peripheral and tumor-infiltrating NK cells exhibited conserved patterns of inhibitory receptor over-expression, this did not explain the observed defects in NK surveillance in bladder tumors. Rather, TME-specific TGF-β and metabolic perturbations such as hypoxia directly suppressed NK cell function. Specifically, an oxygen-dependent reduction in signaling through SLAMF6 was mechanistically responsible for poor NK cell function, as tumor-infiltrating NK cells cultured ex vivo under normoxic conditions exhibited complete restoration of function, while deletion of SLAMF6 abrogated NK cell cytolytic function even under normoxic conditions. Collectively, this work highlights the role of tissue-specific factors in dictating NK cell function, and implicates SLAMF6 signaling as a rational target for immuno-modulation to improve NK cell function in bladder cancer. Graphical

10 November 2021 in Journal for ImmunoTherapy of Cancer
Verified
Conference Paper
Open access
PDF file
BSBerengere Salome
Berengere Salome
JSJohn P. Sfakianos
John P. Sfakianos
ACAndrew Charap
Andrew Charap
AFAdam Farkas
Adam Farkas
DGDaniel Geanon
Daniel Geanon
AHAmir Horowitz
Amir Horowitz
Background Bladder cancer is characterized by a poor prognosis, with muscle-invasive cases harboring a 34–76% 10-year recurrence-free survival rate.1 Neoadjuvant PD-1/PD-L1 blockade strategies have recently been approved by the US Food and Drug Administration for bladder cancer treatment, yet only achieving a complete response rate of 31–37%, thereby suggesting additional mechanisms of resistance.2 HLA-E is a known inhibitor of NKG2A+ CD8 T cells and NK cell responses. A monoclonal antibody binding to the NKG2A receptor has been developed and proven to restore CD8 T cell and NK cell responses in head and neck cancer, with ongoing clinical trials across multiple tumor indications.3 4 We evaluated the potential role of the HLA-E/NKG2A inhibitory pathway in modulating T cell immunity in bladder cancer. Methods CyTOF was performed on CD8+ T cells from fresh bladder tumors (n=6), as well as on expanded CD8+ T cells from bladder-draining lymph nodes (n=11) and tumors (n=8). Flow cytometry (n=25) and single-cell RNA-sequencing (scRNAseq) (n=13) were performed on cells from fresh bladder tumors. Results Mechanisms of tumor escape from CD8+ T cell recognition include impairment of antigen presentation. Accordingly, we found a significant reduction of HLA class I expression on tumors. However, expression of DNAM-1-activating ligands (e.g. CD112,CD155) on bladder tumors was retained, indicating a possible role for TCR-independent activation pathways traditionally ascribed to natural killer (NK) cells. Using mass cytometry and scRNAseq, we observed that acquisition of NKG2A on tumor-derived PD-1+ CD8+ T cells promotes tissue-resident memory features alongside diminished CD28 expression and significantly weaker sensitivity to CD3/CD28-signaling. However, NKG2A+ CD8 T cells possess a proliferative advantage with enhanced expression of DNAM-1 and cytolytic machinery.Strikingly, we found that NKG2A+PD-1+ CD8 T cells are strongly activated in response to HLA class I-deficient tumors compared to their NKG2A- PD-1+ CD8 T cell counterparts. TCR-independent NK-like function by NKG2A+ CD8 T cell is partly mediated by the DNAM-1 pathway and inhibited by HLA-E. NKG2A+ CD8 T cell functions are restored upon NKG2A blockade, where efficiency positively correlates with HLA-E expression on bladder tumors. Conclusions Collectively, our data indicate that NKG2A+ CD8 T cells display a strong capacity for TCR-independent activation that enables them to circumvent bladder tumor evasion mechanisms. NKG2A+ CD8 T cells lack expression of CD28 suggesting a lower susceptibility to PD-1-mediated inhibiton. Our data suggest a need for thorough reappraisal of current protocols that assess CD8 T cell exhaustion and for strategies to restore their antitumor functions. References Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, Lotan Y. Bladder cancer. Nat Rev Dis Primers 2017 April 13;3:17022. doi: 10.1038/nrdp.2017.22. PMID: 28406148. Rouanne M, Bajorin DF, Hannan R, Galsky MD, Williams SB, Necchi A, Sharma P, Powles T. Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder. Eur Urol Oncol 2020 December;3(6):728–738. doi: 10.1016/j.euo.2020.06.009. Epub 2020 Nov 8. PMID: 33177001. André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, Rossi B, Remark R, Breso V, Bonnet E, Habif G, Guia S, Lalanne AI, Hoffmann C, Lantz O, Fayette J, Boyer-Chammard A, Zerbib R, Dodion P, Ghadially H, Jure-Kunkel M, Morel Y, Herbst R, Narni-Mancinelli E, Cohen RB, Vivier E. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK Cells. Cell 2018 December 13;175(7):1731–1743.e13. doi: 10.1016/j.cell.2018.10.014. Epub 2018 Nov 29. PMID: 30503213; PMCID: PMC6292840. van Hall T, André P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer 2019 October 17;7(1):263. doi: 10.1186/s40425-019-0761-3. PMID: 31623687; PMCID: PMC6798508.